Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making
Jun 10, 2009
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people.
 |
Jun 3, 2009
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body.
|
Apr 22, 2009
Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.
|
Apr 22, 2009
By:George Koroneos, Online Content & News Editor
The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.
|
Apr 1, 2009
From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.
|
Mar 12, 2009
By:Walter Armstrong, Senior Editor
The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.
|
Mar 5, 2009
By:George Koroneos, Online Content & News Editor
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
|
Mar 4, 2009
By:George Koroneos, Online Content & News Editor
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
If you're searching for a new business location, attend the Business Facilities LiveXchange event and learn from location experts, meet with economic developers, and network with peers, all at no cost to you!